I. Introduction: The Case for Non-Invasive Intervention

Approximately 313 million major surgical procedures are performed worldwide each year (Weiser et al., 2015), an extraordinary achievement in human capability and, simultaneously, an enormous physiological burden: surgical site infections affect 2–5% of procedures in developed nations and up to 20% in resource-limited settings (WHO, 2018), and post-operative complications including venous thromboembolism, pneumonia, and cardiac events contribute substantially to overall surgical mortality. Minimally invasive surgery, laparoscopic, robotic, catheter-based, has reduced but not eliminated these costs; every approach requiring tissue penetration carries the fundamental burdens of tissue violation.

Focused acoustic tissue intervention represents a categorically different approach: achieving surgical objectives, destroying, dissolving, or structurally disrupting target tissue, through the non-invasive application of acoustic energy from outside the body. This approach is clinically validated for an expanding range of conditions. The paper is explicit about its scope: it does not propose that conventional surgery should or can be replaced by acoustic approaches in all cases, many indications require capabilities acoustic methods cannot provide, complex reconstruction, multi-tissue repair, direct visualization and manipulation. It proposes that for an important and expanding subset of indications, primarily the destruction or dissolution of discrete pathological structures, acoustic approaches offer clinical advantages that are currently underutilized, and that the resonant selectivity extension proposed here may further expand that subset.

II. Scientific Foundation: Three Decades of Acoustic Tissue Intervention

The clinical evidence base for focused acoustic tissue intervention is substantial, multi-decade, and spans multiple clinical specialties. The Christos™ framework builds on three established clinical technologies whose mechanisms, outcomes, and limitations are well-characterized in the peer-reviewed literature.

2.1 Extracorporeal Shock Wave Lithotripsy (ESWL)

ESWL, the destruction of kidney and urinary tract stones using externally focused acoustic shock waves, has been standard clinical practice since its introduction by Chaussy et al. in 1980 and FDA approval in 1984. With over 35 years of clinical use, it is the foundational proof of concept for acoustic tissue intervention: acoustic energy can selectively destroy a discrete pathological structure while leaving surrounding soft tissue largely intact. Skolarikos et al.'s (2006) systematic review and meta-analysis in European Urology analyzed outcomes across 7,047 patients, documenting stone-free rates of 68–88% for stones under 20mm with major complication rates under 1%. The acoustic selectivity of ESWL derives from the marked difference in acoustic impedance between crystalline stone material (~5.7 MRayl) and soft tissue (~1.5–1.7 MRayl); Lingeman et al. (2009) comprehensively reviewed this biophysics, confirming that tissue selectivity arises fundamentally from material property differences. The technique has extended successfully to other calcified structures: Harniman et al. (2004) documented 58–91% good-to-excellent outcomes for calcific shoulder tendinitis, and Rompe et al. (2009) demonstrated outcomes equivalent to surgery for plantar fasciitis in a randomized controlled trial.

2.2 High-Intensity Focused Ultrasound (HIFU)

HIFU extends acoustic tissue intervention from mechanical fragmentation to thermal ablation of soft tissue, focusing high-intensity beams to raise focal temperature to 60–85°C within seconds, producing coagulative necrosis without incision or ionizing radiation. HIFU has FDA clearance for uterine fibroids (ExAblate, 2004), essential tremor (ExAblate Neuro, 2016), bone metastasis palliation (2012), and prostate tissue ablation (2015), with active Phase II/III trials for breast, liver, pancreatic, and kidney cancer. Stewart et al.'s (2003) pivotal registration trial in the New England Journal of Medicine demonstrated significant symptom improvement in 71% of fibroid patients at 6 months, with mean fibroid non-perfused volume reduction of 51.4% ± 32.7%, performed without general anesthesia. Illing et al.'s (2005) meta-analysis of 1,038 hepatocellular carcinoma patients documented complete tumor necrosis rates of 71–100% for tumors under 5cm. HIFU's thermal mechanism has real limitations: it produces non-selective tissue destruction at the focal point regardless of composition, requires real-time MRI guidance, and is less effective when the beam path crosses bone or gas-containing structures (Chen et al., 2010).

2.3 Histotripsy: Non-Thermal Acoustic Tissue Ablation

Histotripsy, developed by Xu et al. (2004) at the University of Michigan, is the most directly relevant existing technology to the Christos™ framework. Unlike HIFU's thermal mechanism, histotripsy uses precisely controlled acoustic cavitation, the generation and violent collapse of microbubbles within tissue, to mechanically homogenize tissue without heat, so adjacent structures including blood vessels are not thermally damaged even at the ablation boundary. Hall et al. (2007) demonstrated homogeneous tissue liquefaction with sharp, sub-millimeter boundaries. Parsons et al. (2006) demonstrated complete histotripsy ablation of 3cm liver tumor volumes in animal models with clear margins; a Phase I clinical trial for hepatocellular carcinoma (NCT03741881) has completed enrollment with results pending. Stiles et al. (2019) demonstrated cardiac tissue ablation in animal models with no steam pops, no char, and no collateral injury, outperforming radiofrequency ablation on tissue specificity. Maxwell et al. (2011) demonstrated histotripsy thrombus dissolution rates significantly exceeding tPA alone without the bleeding risk of systemic thrombolysis. Vlaisavljevich et al. (2015) systematically compared cavitation thresholds across 17 tissue types, confirming that acoustic mechanical properties differ measurably between pathological and healthy tissue.

2.4 The State of the Field

III. The Resonant Selectivity Principle

The central scientific hypothesis of the framework is that pathological tissue can be preferentially targeted by acoustic fields tuned to the pathological tissue's specific resonant frequency, because acoustic energy deposition in the target would be significantly greater than in surrounding healthy tissue whose resonant frequency differs.

3.1 Physical Basis of Tissue Acoustic Signatures

Every tissue has a characteristic acoustic impedance (Z = density × acoustic velocity) and resonant frequency spectrum determined by microstructural geometry and elastic properties, well-characterized in the acoustic literature and routinely exploited in diagnostic ultrasound imaging.

The acoustic impedance differences between pathological and healthy tissue, particularly for fibrotic, calcified, and neoplastic tissue types, provide the acoustic contrast that diagnostic imaging already exploits. The resonant selectivity principle proposes to exploit that same contrast therapeutically. Vlaisavljevich et al. (2015) documented 3–5 fold differences in histotripsy cavitation threshold between tissue types, and Coussios and Roy (2008) established in Annual Review of Fluid Mechanics that local tissue mechanical properties determine the acoustic threshold and efficiency of cavitation-based disruption. The resonant selectivity principle proposes to make this tissue-type selectivity explicit and programmable through systematic acoustic characterization and frequency matching.

3.2 The Boundary Discrimination Index

The framework introduces the Boundary Discrimination Index (BDI), a proposed quantitative measure of acoustic contrast between a target tissue and its surrounding structures, defined as the ratio of the difference in acoustic resonance parameters between target and surrounding tissue to the measurement uncertainty of those parameters. High BDI (kidney stones versus renal parenchyma) predicts high resonant selectivity; low BDI (early-stage soft tissue tumors, whose acoustic properties may closely resemble surrounding tissue) predicts more conservative treatment parameters.

IV. The Christos™ Acoustic Dissolution System

The system integrates the resonant selectivity principle with the blueprint-controlled field architecture of the Weaver's Loom fabrication platform and the biofield diagnostic capabilities of the Christos™ C1 Diagnostician, proposed to produce an adaptive, patient-specific, real-time-guided acoustic surgical platform.

4.1 System Components

A proposed acoustic transducer array, a phased array of focused transducers, would allow electronic steering of the focal point and, through phase-controlled multi-source interference, the creation of complex three-dimensional pressure field geometries beyond what a single transducer produces; Clement and Hynynen (2000) demonstrated electronically steered HIFU arrays capable of multiple simultaneous foci in Physics in Medicine and Biology, establishing the technical feasibility of this array architecture. A proposed acoustic resonance profiling subsystem would characterize the target tissue's acoustic resonant signature before and during treatment via low-amplitude broadband pulses, consistent with established diagnostic acoustic literature confirming tissue acoustic properties are measurable with sufficient resolution to distinguish pathological from healthy tissue in most clinical targets (Wells, 2006; Cobbold, 2007). The proposed Christos™ C1 biofield monitoring system would provide real-time multi-modality (electromagnetic, acoustic, biophotonic) coherence tracking, and a proposed Research Operating System (ROS) adaptive control layer would manage the procedure through a formal five-phase protocol with real-time field adjustment.

4.2 The Proposed Five-Phase Protocol

V. Clinical Applications and Evidence Alignment

The following applications represent the primary proposed targets, ordered by BDI and by the strength of the existing acoustic intervention evidence base each builds on.

5.1 Kidney Stones and Urinary Calculi

ESWL for urinary calculi is the gold standard of acoustic selectivity. The framework's proposed contribution is resonant frequency profiling of individual stones, since different stone compositions (calcium oxalate monohydrate vs. dihydrate vs. calcium phosphate) have measurably different acoustic properties (Dretler, 1988) and therefore different optimal dissolution frequencies. Patient-specific resonant profiling of stone composition before treatment selection is proposed to potentially improve first-session clearance rates beyond the 68–88% reported by Skolarikos et al. (2006) for undifferentiated ESWL protocols.

5.2 Vascular Thrombus Dissolution

DVT affects an estimated 1–2 per 1,000 people annually (Heit, 2015). Current anticoagulant therapy prevents clot extension but does not reliably dissolve established thrombus; catheter-directed thrombolysis adds bleeding risk. Maxwell et al. (2011) demonstrated histotripsy thrombus dissolution superior to tPA alone; the framework proposes extending this with resonant profiling of thrombus acoustic properties to optimize the dissolution field for specific thrombus composition and age.

5.3 Uterine Fibroids

Uterine fibroids affect 20–40% of women of reproductive age (Baird et al., 2003). HIFU is FDA-approved but limited by MRI guidance requirements and suboptimal outcomes for posterior fibroids and large volumes. The framework's proposed non-thermal dissolution mechanism, targeting the fibroid's elevated acoustic impedance from collagen-rich composition rather than thermal necrosis, is proposed to potentially address posterior fibroid accessibility and reduce the multiple sessions typically required for large fibroids.

5.4 Hepatocellular Carcinoma and Liver Metastases

Primary liver cancer is often inoperable at presentation due to underlying cirrhotic disease or location adjacent to major vessels. HIFU and histotripsy have demonstrated efficacy in selected patients (Illing et al., 2005); the resonant selectivity approach is proposed as specifically relevant for peri-vascular tumors, where HIFU's thermal approach risks collateral vessel injury.

5.5 Cardiac Arrhythmia Ablation

Atrial fibrillation affects an estimated 33.5 million people globally (Chugh et al., 2014); catheter ablation currently requires femoral vein insertion and transseptal puncture, with procedure times of 2–4 hours and complications including cardiac tamponade and esophageal injury. Stiles et al. (2019) demonstrated histotripsy cardiac tissue ablation without catheter access in animal models, a result the framework proposes to build toward, though human translation, as the source notes, requires careful safety characterization given respiratory and cardiac motion and rib cage acoustic barriers.

5.6 Calcific Atherosclerotic Plaque

Calcified coronary and peripheral arterial plaque, with acoustic impedance 3–5× that of the arterial wall, represents one of the highest-BDI targets. Intravascular lithotripsy already demonstrates that acoustic energy can fracture calcified plaque to improve vessel compliance (Brodmann et al., 2017), but requires catheter delivery; the framework proposes transcutaneous resonant field delivery for appropriate superficial peripheral vessels as a non-catheter alternative.

VI. The Coherence Restoration Component

A distinguishing proposed feature relative to existing acoustic tissue intervention is a coherence restoration protocol following the dissolution phase, addressing a limitation common to all tissue ablation approaches: following any ablation, whether surgical, thermal, or acoustic, the body's response involves inflammation, macrophage recruitment, and wound healing that typically results in fibrotic scar formation rather than regenerative tissue replacement. This is biologically appropriate for wound healing but may be suboptimal following ablation of benign structures (fibroids, calcifications, thrombus) where true regeneration rather than scar replacement is the optimal outcome.

The proposed protocol draws on the LIPUS hard tissue regeneration evidence base (Busse et al., 2002; Scheven et al., 2009), acoustic manipulation of endogenous stem cells (Wullkopf et al., 2021), and photobiomodulation for tissue repair (Hamblin, 2017), applying a coherent field environment to the post-ablation zone intended to support regenerative rather than fibrotic healing. The paper is explicit that this scientific basis is strongest for hard tissue defects, where LIPUS-guided regeneration is clinically validated, and more exploratory for soft tissue applications, where translation from LIPUS bone healing to soft tissue regenerative guidance is mechanistically plausible but has not yet been directly validated in the post-ablation context, pending the AD-005 study described below.

VII. Proposed Research Program and Regulatory Pathway

7.2 Regulatory Pathway

The system is classifiable as a Class III medical device under FDA's classification framework, the same class as approved HIFU and lithotripsy devices. The predicate device pathway (510(k) substantial equivalence to approved HIFU or histotripsy systems) is potentially applicable for initial indications closely paralleling existing approved applications; novel indications will require PMA approval with full clinical evidence. Histotripsy received FDA Breakthrough Device designation for liver cancer treatment, and the framework's resonant selectivity and coherence restoration components may qualify for similar designation for appropriate indications. Phase I safety studies (AD-003) would be conducted under IND application establishing the safety profile of the resonant frequency selection approach relative to existing acoustic thrombolysis literature (Maxwell et al., 2011; Prokop et al., 2007).

VIII. Discussion

8.1 What This Framework Is and Is Not

The framework proposes a specific extension of well-established acoustic tissue intervention science, adding resonant frequency selectivity, coherent multi-source field geometry, and adaptive real-time monitoring, to existing approaches already validated and approved for clinical use. It does not propose that acoustic energy can achieve effects physical law does not support; it proposes that the specific acoustic properties of pathological tissue can be exploited more precisely and systematically than current approaches achieve. The existing clinical evidence base, three decades of lithotripsy, two decades of HIFU, and an emerging histotripsy literature, provides proof of concept for non-invasive acoustic tissue intervention as a category; the resonant selectivity extension is a specific technical innovation within that established category, not a departure from established physical principles.

8.2 Honest Assessment of What Remains to Be Established

The source material states its own limitations directly, and this page preserves them in full. Resonant selectivity in vivo: the tissue acoustic property differences documented in the literature provide a physical basis for resonant selectivity, but in vivo characterization is complicated by respiratory motion, tissue heterogeneity, and overlying structures; whether resonant profiling provides clinically meaningful improvements over existing non-selective HIFU or histotripsy requires head-to-head clinical comparison (AD-001, AD-002). Post-ablation coherence restoration: the LIPUS regeneration evidence base is well-established for bone and dental hard tissue; translation to soft tissue regeneration following acoustic ablation is physically motivated and mechanistically plausible but requires dedicated preclinical and clinical evaluation (AD-005). C1 biofield monitoring in surgical context: the adaptive control system's reliance on C1 monitoring makes the C1's own clinical validation program, described in a companion diagnostic white paper, prerequisite for the dissolution system's full adaptive control capability. Cardiac applications: non-invasive transcutaneous delivery to cardiac tissue with sufficient precision for arrhythmia ablation faces specific technical challenges, respiratory and cardiac motion, rib cage acoustic barriers, and cardiac cycle gating; the animal model results of Stiles et al. (2019) are promising but human translation requires careful safety characterization.

8.3 The Clinical Opportunity

The global burden of conditions potentially addressable by non-invasive acoustic tissue intervention is substantial: 313 million major surgical procedures annually (Weiser et al., 2015), 1–2 per 1,000 people annually with DVT (Heit, 2015), 33.5 million people with atrial fibrillation (Chugh et al., 2014), and 20–40% of women with uterine fibroids (Baird et al., 2003). Even a modest expansion of the acoustic intervention toolkit beyond current HIFU and histotripsy capabilities represents a clinical opportunity of significant scale, pending the validation this paper proposes to pursue.

IX. Conclusion

Focused acoustic tissue intervention has a 35-year track record of clinical validation and an expanding range of approved applications. The Christos™ Acoustic Dissolution Framework proposes to extend these established capabilities through resonant frequency selectivity, coherent multi-source field geometry, adaptive real-time monitoring, and post-ablation coherence restoration, extensions the paper describes as physically motivated, grounded in the existing bioacoustics literature, and testable through the proposed research program. The paper is explicit that clinical validation of the resonant selectivity approach and the coherence restoration component remains to be completed, and presents the framework as a theoretically grounded proposal for extending established acoustic tissue intervention science, not as a validated clinical system.

References

Baird, D.D., et al. (2003). High cumulative incidence of uterine leiomyoma in black and white women. American Journal of Obstetrics and Gynecology, 188(1), 100–107.
Brodmann, M., et al. (2017). Safety and performance of lithoplasty for calcified peripheral artery obstructions. Journal of the American Heart Association, 6(6), e005538.
Busse, J.W., et al. (2002). The effect of low-intensity pulsed ultrasound therapy on time to fracture healing. CMAJ, 166(4), 437–441.
Busse, J.W., et al. (2009). Ultrasound and shockwave therapy for acute fractures in adults. Cochrane Database of Systematic Reviews, 3, CD008579.
Chaussy, C., et al. (1980). Extracorporeally induced destruction of kidney stones by shock waves. The Lancet, 316(8207), 1265–1268.
Chen, W.Z., et al. (2010). Progress of clinical high-intensity focused ultrasound. Journal of Ultrasound in Medicine, 22(7), 647–660.
Chugh, S.S., et al. (2014). Worldwide epidemiology of atrial fibrillation. Circulation, 129(8), 837–847.
Clement, G.T., & Hynynen, K. (2000). Ultrasound phase-array focusing through tissue heterogeneity. Physics in Medicine and Biology, 45(2), 373–387.
Cobbold, R.S.C. (2007). Foundations of Biomedical Ultrasound. Oxford University Press.
Coussios, C.C., & Roy, R.A. (2008). Applications of acoustics and cavitation to noninvasive therapy and drug delivery. Annual Review of Fluid Mechanics, 40, 395–420.
Dretler, S.P. (1988). Stone fragility, a new therapeutic distinction. Journal of Urology, 139(5), 1124–1127.
Hall, T.L., et al. (2007). Histotripsy of the prostate: dose effects in a chronic canine model. Urology, 69(4), 747–751.
Hamblin, M.R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337–361.
Harniman, E., et al. (2004). Extracorporeal shock wave therapy for calcific and noncalcific tendonitis of the rotator cuff. Journal of Hand Therapy, 17(2), 132–151.
Heit, J.A. (2015). Epidemiology of venous thromboembolism. Nature Reviews Cardiology, 12(8), 464–474.
Illing, R.O., et al. (2005). The safety and feasibility of extracorporeal HIFU for liver and kidney tumours. British Journal of Cancer, 93(8), 890–895.
Lingeman, J.E., et al. (2009). Shock wave lithotripsy: advantages, limitations, and myths. Journal of Endourology, 23(10), 1641–1648.
Maxwell, A.D., et al. (2011). Noninvasive thrombolysis using pulsed ultrasound cavitation therapy, histotripsy. Ultrasound in Medicine and Biology, 37(12), 1998–2007.
Parsons, J.E., et al. (2006). Pulsed cavitational ultrasound therapy for controlled destruction of soft tissue. Proceedings of SPIE, 6147, 61470E.
Prokop, A.F., et al. (2007). Pulsed ultrasound enhances thrombolysis of artificial clots with urokinase. Ultrasound in Medicine and Biology, 33(12), 1903–1908.
Rompe, J.D., et al. (2009). Eccentric loading compared with shock wave treatment for chronic insertional Achilles tendinopathy. Journal of Bone and Joint Surgery, 90(1), 52–61.
Scheven, B.A., et al. (2009). Low-frequency ultrasound stimulates reparative dentinogenesis. Journal of Dental Research, 88(10), 923–928.
Skolarikos, A., et al. (2006). Extracorporeal shock wave lithotripsy 25 years later: complications and their prevention. European Urology, 50(5), 981–990.
Stewart, E.A., et al. (2003). Focused ultrasound treatment of uterine fibroid tumors. American Journal of Obstetrics and Gynecology, 189(1), 48–54.
Stiles, M.K., et al. (2019). A prospective randomized pilot study of cardiac histotripsy ablation of pulmonary vein sleeves in a porcine model. Circulation: Arrhythmia and Electrophysiology, 12(4), e006893.
Vlaisavljevich, E., et al. (2015). Effects of tissue mechanical properties on susceptibility to histotripsy-induced tissue damage. Physics in Medicine and Biology, 59(2), 253–270.
Weiser, T.G., et al. (2015). Estimate of the global volume of surgery in 2012. The Lancet, 385(Suppl 2), S11.
Wells, P.N.T. (2006). Ultrasound imaging. Physics in Medicine and Biology, 51(13), R83–R98.
World Health Organization. (2018). Global Guidelines for the Prevention of Surgical Site Infection. WHO Press.
Wullkopf, L., et al. (2021). The waves that make the pattern: a review on acoustic manipulation in biomedical research. Biomaterials Science, 9(12), 4749–4770.
Xu, Z., et al. (2004). A new strategy to enhance cavitational tissue erosion using a high-intensity, initiating sequence. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 51(10), 1412–1424.

Intellectual Property & Disclosure Statement

The resonant selectivity principle, the Boundary Discrimination Index concept, the proposed five-phase acoustic dissolution protocol, and the integration of the cited evidence base into one coherence-organized surgical framework are original work of Joshua Farrior, claimed as intellectual property of Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.

Held under NDA: the full mathematical specification of the Christos™ MoR predictive framework; exact treatment frequencies, amplitudes, and transducer array specifications; and the BDI calculation methodology at implementation precision. Nothing in this paper constitutes medical advice, and the framework's own stated limitations in Section VIII apply throughout.